We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $440M
1-Year Est. Return 28.33%
This Fund
S&P 500
This Quarter Est. Return
+3.26%
1 Year Est. Return
+28.33%
3 Year Est. Return
+79.73%
5 Year Est. Return
-17.94%
10 Year Est. Return
AUM
$796M
AUM Growth
+$15.9M
Cap. Flow
-$305K
Cap. Flow %
-0.04%
Top 10 Hldgs %
100%
Holding
13
New
Increased
1
Reduced
Closed
2

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$90.2M

Sector Composition

Rank Sector Weight
1 Miscellaneous 95.43%
2 Healthcare 4.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPY icon
1
State Street SPDR S&P 500 ETF Trust
SPY
$804B
$624M 78.43%
1,146,979
+172,338
+18% +$90.2M
INDA icon
2
iShares MSCI India ETF
INDA
$6.51B
$135M 17%
2,425,144
FHTX icon
3
Foghorn Therapeutics
FHTX
$248M
$9.05M 1.14%
1,573,761
ORIC icon
4
Oric Pharmaceuticals
ORIC
$1.32B
$7M 0.88%
989,410
ALEC icon
5
Alector
ALEC
$208M
$5.94M 0.75%
1,307,858
PMVP icon
6
PMV Pharmaceuticals
PMVP
$78M
$4.26M 0.53%
2,627,643
ME
7
DELISTED
23andMe Holding Co
ME
$4.01M 0.5%
512,156
TNYA icon
8
Tenaya Therapeutics
TNYA
$149M
$3.15M 0.4%
1,015,705
RAPT
9
DELISTED
RAPT Therapeutics
RAPT
$2.01M 0.25%
82,237
SRZN icon
10
Surrozen
SRZN
$200M
$960K 0.12%
87,696
SRZNW
11
DELISTED
Surrozen Inc Warrant
SRZNW
$2.84K ﹤0.01%
170,833
GLD icon
12
SPDR Gold Trust
GLD
$147B
-432,271
Closed -$88.9M
NGM
13
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
-992,168
Closed -$1.58M

Similar funds

Euclidean Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Euclidean Capital held 13 positions worth $796M, up 2% from $780M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Euclidean Capital's Q2 2024 filing shows 1 increased and 2 closed positions. The largest sale was SPDR Gold Trust, an estimated $88.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 95% of assets, up from 93% a quarter earlier, followed by Healthcare.

  • Euclidean Capital added most to State Street SPDR S&P 500 ETF Trust in Q2 2024, an estimated $90.2M increase.
  • Euclidean Capital fully exited SPDR Gold Trust in Q2 2024, selling an estimated $88.9M.
  • Euclidean Capital's ten largest holdings make up 100% of its $796M portfolio in Q2 2024.
  • Euclidean Capital opened 0 new positions and closed 2 in Q2 2024.
  • Euclidean Capital's portfolio value rose 2% quarter-over-quarter to $796M.

Based on Euclidean Capital's 13F filing for Q2 2024, filed 14 Aug 2024.